Transarterial oily chemoembolization combined with interstitial laser thermotherapy for treatment of hepatocellular carcinoma.
- Author:
Ze-jian ZHOU
1
;
Rong-de XU
;
Wei-ke LI
;
Wen-xing ZHUANG
;
Li-gong LU
;
Pei-jian SHAO
;
Xiao-ming CHEN
;
Peng-fei LUO
Author Information
- Publication Type:Journal Article
- MeSH: Carcinoma, Hepatocellular; therapy; Chemoembolization, Therapeutic; Humans; Hyperthermia, Induced; Lasers; Liver Neoplasms; therapy; Survival Rate; Treatment Outcome
- From: Journal of Southern Medical University 2007;27(12):1866-1868
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the therapeutic effects and adverse effects of transarterial oily chemoembolization combined with interstitial laser thermotherapy (TOCE+ILT) in the treatment of hepatocellular carcinoma.
METHODSTotally 120 patients with hepatocellular carcinoma were randomized into two groups and received interventions with TOCE+ILT or TOCE combined with percutaneous ethanol injection (TOCE+PEI). The treatment was repeated when necessary until the tumor was completely ablated, after which the therapeutic effects were evaluated and the patients were the followed up for observing long-term clinical outcome.
RESULTSOf the 120 patients enrolled in this observation, 105 were followed up for two years (54 in TOCE+ILT group and 51 in TOCE+PEI group). The complete tumor necrosis rate of TOCE+ILT group was significantly higher than that of the TOCE+PEI group (84.8% vs 73.9%,Chi(2)=4.405, P=0.036), and TOCE+ILT was associated with a significantly higher negative conversion rate of AFP positivity (77.8% vs 56.1%, Chi(2)=4.592, P=0.032). The 1-year survival rate were similar between two groups, but the 2-year survival rate was significantly higher in patients with TOCE+ILT (79.6% vs 60.8%, Chi(2)=4.477, P=0.034). The hepatic function was comparable between the two groups before treatment, and 1 week after treatment, the ALT level in patients undergoing TOCE+ILT was significantly lower than that in patients with TOCE+PEI (95.90-/+56.06 U/L vs 116.31-/+45.27 U/L, t=2.04, P=0.043). Post-embolization syndrome was observed in the patients in two groups, but no severe adverse events were found.
CONCLUSIONTOCE+ILT has good therapeutic effects and mild side effects in the treatment of hepatocellular carcinoma.